New Search

Your search found 17 records, sorted by year and then date of acquisition.

1. Long-Term Outcomes After Randomization to Buprenorphine/Naloxone Versus Methadone in a Multi-Site Trial. doc type
  Hser, Yih-Ing ; Evans, Elizabeth ; Huang, David ; Weiss, Roger D. ; Saxon, Andrew J. ; Carroll, Kathleen M. ; Woody, George E. ; Liu, David S. ; Wakim, Paul G. ; Matthews, Abigail G. ; Hatch-Maillette, Mary A. ; Jelstrom, Eve ; Wiest, Katharina L. ; McLaughlin, Paul ; Ling, Walter
 Addiction 2016;111(4):695-705. [doi: 10.1111/add.13238].
 
2. Treatment Outcomes in Opioid Dependent Patients with Different Buprenorphine/Naloxone Induction Dosing Patterns and Trajectories. doc type
  Jacobs, Petra ; Ang, Alfonso ; Hillhouse, Maureen P. ; Saxon, Andrew J. ; Nielsen, Suzanne ; Wakim, Paul G. ; Mai, Barbara E. ; Mooney, Larissa J. ; Potter, Jennifer Sharpe ; Blaine, Jack D.
 American Journal on Addictions 2015;24:667-675. [doi: 10.1111/ajad.12288].
 
3. Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study. doc type
  Schulte, Marya T. ; Hser, Yih-Ing ; Saxon, Andrew J. ; Evans, Elizabeth ; Li, Libo ; Huang, David ; Hillhouse, Maureen P. ; Thomas, Christie ; Ling, Walter
 Journal of Community Health 2015;40(5):940-947. [doi: 10.1007/s10900-015-0016-2].
 
4. Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study. doc type
  Teruya, Cheryl ; Schwartz, Robert P. ; Mitchell, Shannon G. ; Hasson, Albert L. ; Thomas, Christie ; Buoncristiani, Samantha H. ; Hser, Yih-Ing ; Wiest, Katharina ; Cohen, Allan J. ; Glick, Naomi ; Jacobs, Petra ; McLaughlin, Paul ; Ling, Walter
 Journal of Psychoactive Drugs 2014;46(5):412-426. [doi: 10.1080/02791072.2014.921743].
 
5. HIV Risk Reduction with Buprenorphine-Naloxone or Methadone: Findings from A Randomized Trial. doc type
  Woody, George E. ; Bruce, R. Douglas ; Korthuis, P. Todd ; Chhatre, Sumedha ; Hillhouse, Maureen P. ; Jacobs, Petra ; Sorensen, James L. ; Saxon, Andrew J. ; Metzger, David S. ; Ling, Walter
 Journal of Acquired Immune Deficiency Syndromes 2014;66(3):288-293. [doi: 10.1097/QAI.0000000000000165].
 
6. Genetic Variation in OPRD1 and the Response to Treatment for Opioid Dependence with Buprenorphine in European American Females. doc type
  Clarke, Toni-Kim ; Crist, Richard C. ; Ang, Alfonso ; Ambrose-Lanci, Lisa ; Lohoff, Falk W. ; Saxon, Andrew J. ; Ling, Walter ; Hillhouse, Maureen P. ; Bruce, R. Douglas ; Woody, George E. ; Berrettini, Wade H.
 Pharmacogenomics Journal 2014;14:303-308. [doi: 10.1038/tpj.2013.30].
 
7. Treatment Retention Among Patients Randomized to Buprenorphine/Naloxone Compared to Methadone in a Multi-Site Trial. doc type
  Hser, Yih-Ing ; Saxon, Andrew J. ; Huang, David ; Hasson, Albert ; Thomas, Christie ; Hillhouse, Maureen ; Jacobs, Petra ; Teruya, Cheryl ; McLaughlin, Paul ; Wiest, Katharina ; Cohen, Allan J. ; Ling, Walter
 Addiction 2014;109(1):79-87. [doi: 10.1111/add.12333].
 
8. Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings from Starting Treatment with Agonist Replacement Therapies (START). doc type
  Potter, Jennifer Sharpe ; Marino, Elise N. ; Hillhouse, Maureen P. ; Nielsen, Suzanne ; Wiest, Katharina ; Canamar, Catherine P. ; Martin, Judith A. ; Ang, Alfonso ; Baker, Rachel ; Saxon, Andrew J. ; Ling, Walter
 Journal of Studies on Alcohol and Drugs 2013;74(4):605-613..
 
9. An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans. doc type
  Crist, Richard C. ; Clarke, Toni-Kim ; Ang, Alfonso ; Ambrose-Lanci, Lisa ; Lohoff, Falk W. ; Saxon, Andrew J. ; Ling, Walter ; Hillhouse, Maureen P. ; Bruce, R. Douglas ; Woody, George E. ; Berrettini, Wade
 Neuropsychopharmacology 2013;38:2003-2010. [doi: 10.1038/npp.2013.99].
 
10. Buprenorphine/Naloxone and Methadone Effects on Laboratory Indices of Liver Health: A Randomized Trial. doc type doc type
  Saxon, Andrew J. ; Ling, Walter ; Hillhouse, Maureen P. ; Thomas, Christie ; Hasson, Albert ; Ang, Alfonso ; Doraimani, Geetha ; Tasissa, Gudaye ; Lokhnygina, Yuliya ; Leimberger, Jeffrey D. ; Bruce, R. Douglas ; McCarthy, John ; Wiest, Katharina ; McLaughlin, Paul ; Bilangi, Richard ; Cohen, Allan J. ; Woody, George E. ; Jacobs, Petra
 Drug and Alcohol Dependence 2013;128(1-2):71-76. [doi: 10.1016/j.drugalcdep.2012.08.002].
 
11. Protocol: NIDA-CTN-0027: Starting Treatment with Agonist Replacement Therapies (START). doc type
  Ling, Walter ; Saxon, Andrew J.
 Presented at the American Public Health Association (APHA) annual meeting, Washington, DC, Oct. 28 - Nov. 2, 2011.
 
12. START Study Retention: Perspectives of Suboxone Dropouts. doc type
  Teruya, Cheryl ; Thomas, Christie ; Rosensteel, Anya ; Hasson, Albert L. ; Hillhouse, Maureen P. ; Hser, Yih-Ing ; Ling, Walter
 Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Scottsdale, AZ, June 12-17, 2010.
 
13. Feasibility of Conducting Genetics Research at Community Treatment Programs. doc type
  Sonne, Susan C. ; Gentilin, Stephanie ; Sampson, Royce ; DeVane, Lindsay ; Thomas, Christie ; Berrettini, Wade
 Poster presented at the NIDA Blending Conference, "Blending Addiction Science and Practice: Evidence-Based Treatment and Prevention in Diverse Populations and Settings," Albuquerque, NM, April 22-23, 2010.
 
14. Buprenorphine Treatment of Prescription Opiate Addiction. doc type
  McCarthy, John
 Presented at the NIDA Blending Conference, "Blending Addiction Science and Practice: Evidence-Based Treatment and Prevention in Diverse Populations and Settings," Albuquerque, NM, April 22-23, 2010.
 
15. Addiction Treatments of the Future: The Role of Genetics. doc type
  Kreek, Mary Jeanne ; Haynes, Louise F. ; Cohen, Allan J.
 Presented at the NIDA Blending Conference, "Blending Addiction Science & Treatment: The Impact of Evidence-Based Practices on Individuals, Families, and Communities," Cincinnati, OH, June 2-3, 2008.
 
16. Starting Treatment with Agonist Replacement Therapy: Should I Join? doc type
  NIDA Center for the Clinical Trials Network (NIDA CCTN)
 Bethesda, MD: National Institute on Drug Abuse, 2006.
 
17. Using Buprenorphine in Opioid Treatment Programs. doc type
  Cohen, Allan J.
 Presented at the American Association for the Treatment of Opioid Dependence (AATOD) annual meeting, Atlanta, GA, April 2006.
 

New Search